Novartis

Swiss pharma giant — Kymriah CAR-T pioneer and Cosentyx antibody blockbuster; large-scale biologics manufacturing across Basel and US sites.

Country: Switzerland
Revenue: $52.7B
Employees: ~78,000 emp

GMP EU FDA GMP

Coverage

	CN	EU	US
finance-investment	✓	✓	✓
regenerative-personalized	✓	✓	✓
therapeutics-platforms	✓	✓	✓

Regulatorsfdaemanmpa

Verifiable facts

Fact	Value	Source
Production site	33 manufacturing sites worldwide	prod1.novartis.com · novartis.com
Headcount	75,883 worldwide (2024)	novartis.com
Certification	ISO 9001 certified; cGMP certified for all manufacturing operations	novartis.com
Regulatory approval	Regulated and inspected by authorities including FDA, EMA, WHO, and Swissmedic	novartis.com
Capacity	Large-scale biologics, CAR-T, RLT, and small molecule production capacity; 100% end-to-end US production goal by 2030 medium confidence	biopharmadive.com · bioprocessintl.com · novartis.com
Funding	$23 billion planned investment in US-based infrastructure (2025-2029)	novartis.com · sec.gov

Independent sources: biopharmadive.com · bioprocessintl.com · sec.gov

Technologies

Name	Cluster	Risk
Biologics	therapeutics-platforms	Low	→
CAR-T cell therapy	therapeutics-platforms	Low	→
Corporate biotech accelerators (JLABS, Bayer CoLaborator)	finance-investment	Medium	→
In-vivo gene therapy: AAV and lentiviral vectors	therapeutics-platforms	Medium	→
Personalized & regenerative medicine	regenerative-personalized	Medium	→
Radiopharmaceuticals & theranostics	therapeutics-platforms	High	→

Compiled by BIOECON from primary sources.

Compliance Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.